What's new

Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacoplan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0099/2024

Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacoplan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0099/2024

Jun 5, 2025 - 16:20
 0
Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacoplan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0099/2024
Opinion/decision on a Paediatric investigation plan (PIP): Aspaveli, Pegcetacoplan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: P/0099/2024
Read More

Tags:

Previous Article

GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds

Next Article

Opinion/decision on a Paediatric investigation plan (PIP): Supemtek Tetra (previ...

Related Posts

Ixchiq

Ixchiq

May 28, 2025  0

Human medicines European public assessment report (EPAR): Kymriah, tisagenlecleucel, Date of authorisation: 23/08/2018, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR...

May 15, 2025  0

Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Date of authorisation: 17/06/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

May 19, 2025  0